ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Alto Neuroscience Inc (ANRO) does not present a strong buy opportunity for a beginner investor with a long-term strategy. While the stock shows bullish technical indicators and has potential catalysts in its pipeline, the lack of recent positive news, hedge fund selling trends, and mixed analyst ratings suggest a cautious approach. Holding the stock or waiting for further developments is recommended.
The technical indicators for ANRO are bullish. The MACD is positively expanding above 0, the RSI is neutral at 70.155, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level (20.701) and is approaching its resistance level (R1: 22.844). However, the stock has a 50% chance of declining in the short term (-1.29% in the next day, -2.78% in the next week, -5.15% in the next month).
Bullish technical indicators.
Promising pipeline with ALTO-207 in Phase 2b for treatment-resistant depression, which could be a meaningful commercial opportunity.
Analyst price targets from BofA and H.C. Wainwright suggest significant upside potential ($35-$50).
Hedge funds are selling, with a 159.20% increase in selling activity last quarter.
Mixed analyst ratings, with some downgrades and reduced price targets.
No recent news or significant developments to drive immediate momentum.
High implied volatility (102.
and low IV percentile (9.
suggest limited near-term upside.
Stock trend analysis indicates potential short-term declines.
No financial data available for assessment.
Analyst ratings are mixed. BofA initiated coverage with a Buy rating and a $35 price target, citing ALTO-207's potential as a differentiated treatment option. H.C. Wainwright reiterated a Buy rating with a $50 price target, highlighting the company's robust pipeline. However, Wedbush and Baird have lowered price targets to $21 and $36, respectively, reflecting concerns over the failure of ALTO-101 in Phase 2 trials.
